to 5 carbon atoms and form a linear or branched chain, if appropriate in the form of one of its isomers or their mixtures, and optionally in the form of an acid addition salt, a metal salt or an addition salt with a nitrogen-containing organic base.

Claim 13; amend "claim 12" to read "claim 22".
Claims 14 and 15; amend "claim 1" to read "claim 16".

REMARKS

To meet the Examiner's rejections of claims 1 to 15 under 35 USC 112 first and second paragraphs, the claims have been extensively revised to avoid the language to which objection has been made. New claim 16 corresponds to cancelled claim 1. The various heterocyclic radicals mentioned in this claim are now specifically defined in terms taken from the description at page 2 lines 12 to 13, page 2 lines 17 to 19, and page 3 lines 2 to 5. These amendments make original claim 2 redundant, and this claim has been cancelled.

New claim 17 corresponds to cancelled claim 3 amended in a way similar to claim 1.

It is noted that the term "nitrogen containing substituent capable of forming salts" is no longer used in claims 16 and 17.

It has now been made clear that the acid addition salts referred to in the claims are "pharmaceutically acceptable".

The rejections relating to process claim 8 through 11 have been met by cancellation of these claims. This includes the rejection under 35 USC 103.

Finally, new claim 22, which replaces cancelled claim 12, recites the utility of the claimed compositions and the

165

presence in them of the product of the invention as claimed in the new claim 16 and a synergistically effective amount of a known synergistin of the specified formula.

In these circumstances, it is believed that all the Examiner's rejections under 35 USC 112 have been met by amendment. The rejection under 35 USC 103 no longer applies.

Attention is respectfully directed to an Information Disclosure Statement filed herewith containing the prior art cited against the basic French application. Attention is also respectfully drawn to Patent No. 4590004 having the same assignee as the present application. The compounds of the present invention are believed to be an improvement on those of the granted patent since they are antimicrobial agents per se as well as having a synergistic effect when used with pristinamycin I_A.

Favourable reconsideration and allowance of the application as amended are believed to be in order and are earnestly requested.

Respectfully submitted



Ellsworth H. Mosher
Registration No. 14,717

515, North Washington Street,
Alexandria,
Virginia 22314,
U.S.A.

THE APPLICANT HEREWITH PETITIONS THE PTO TO EXTEND THE TIME FOR RESPONSE AS REQUIRED TO MAKE THE ATTACHED DOCUMENT TIMELY FILED.

PLEASE CHARGE COSTS TO DEPOSIT ACCOUNT 19-4375. STEVENS, DAVIS, MILLER & MOSHER